UBQLN2 and amyotrophic lateral sclerosis: Complementary to the proteomics approach, we subjected our cell panel to mRNA sequencing to gain broad-scale insights into changes at the mRNA level in response to the ALS mutant UBQLN2 (Fig 2A).